Coding guidelines for Agendia's MammaPrint test established by Palmetto GBA

Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test. MammaPrint is Agendia's FDA-cleared breast cancer recurrence test, which has been reimbursed by payors since 2008.

Patients across the United States can now submit claims for the MammaPrint test directly to Palmetto GBA in California where the test results are analyzed. The coding guidelines for healthcare providers are available at the Centers for Medicare and Medicaid Services (CMS) website at>

"Palmetto's decision to include MammaPrint in their reimbursement guidelines will provide greater access to this test for more women and their doctors when faced with difficult treatment decisions around breast cancer," said Dr. Richard Bender, Chief Medical Officer of Agendia.